-+ 0.00%
-+ 0.00%
-+ 0.00%

Chardan Capital Maintains Buy on Metagenomi Therapeutics, Lowers Price Target to $5

Benzinga·07/07/2026 10:59:40
Listen to the news
Chardan Capital analyst Keay Nakae maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Buy and lowers the price target from $7 to $5.